immuno-oncology

Close-up of Benjamin Franklins eyes peering through hundred dollar bills
Biotech

BMS inks $11B biobucks BioNTech deal to join bispecific rush

The deal, which features up to $7.6 billion in milestones, gives BMS a 50% stake in one of the leading assets in the hottest area of immuno-oncology.
Nick Paul Taylor Jun 2, 2025 8:59am
hot

Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific

May 20, 2025 4:47am
End of road sign on street

GSK axes $625M TIGIT drug as midphase data disappoint

May 13, 2025 9:44am
White arrow on a road pointing to the rising sun

Pfizer ties PD-1 drug to 32% cancer risk reduction in phase 3

Apr 28, 2025 7:25am
cartoon of man unplugging from outlet

Apollomics tags out of TYG oncology pact to cut costs

Apr 4, 2025 6:45am
Sketch of lungs

BioNTech posts survival data behind bispecific's phase 3 push

Mar 28, 2025 8:00am